ArticleDiscover oncology2026
Elucidating EGCG' s targets in nasopharyngeal carcinoma through combined cell-based assays and transcriptomic sequencing.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundEpigallocatechin gallate (EGCG) is a catechin, a type of flavonoid that is found in high concentrations in green tea. EGCG has been demonstrated to exhibit anti-proliferative, anti-angiogenic, and pro-apoptotic effects across various cancer cell lines. Furthermore, research indicates that EGCG plays a significant role in the antiproliferation and apoptosis of human nasopharyngeal carcinoma (NPC) cells. The anticancer activity of EGCG is mediated through its interference with multiple hallmarks of cancer; however, the specific targets and mechanisms by which EGCG combats NPC remain unclear.
methodsThis study integrated cell line experiments, network pharmacology, molecular docking, and dynamics simulations to elucidate EGCG’s therapeutic mechanisms in NPC and identify potential targets, while scRNA-seq and MR analyses assessed key target gene-NPC relationships.
resultsAnalysis of the GEO database and RNA sequencing of EGCG-treated NPC (HK-1) cells identified 165 potential targets associated with both EGCG and NPC. Network analysis revealed ten core targets, with EIF2AK2, IFIT1, and STAT1 being key. KEGG and GO analyses highlighted important pathways, including PI3K-Akt, phospholipase D signaling, and EBV infection. Molecular docking showed strong interactions between EGCG and the core targets, and molecular dynamics simulations confirmed complex stability. Finally, differential expression profiling of key target genes at the single-cell level demonstrated a concordance with transcriptomic data, while MR analyses validated the causal relationships between these target genes and the risk of NPC.
conclusionThese findings offer a theoretical basis for the molecular mechanisms underlying EGCG’s therapeutic effects on NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.